NOVO — September 2024
-
Data presented at the European Association for the Study of Diabetes (EASD) annual meeting on Wednesday showed that the highest dose of Novo Nordisk's oral version of amycretin was associated with the greatest weight loss seen in an early-stage trial, answering a question posed when initial results for the amylin/GLP-1 receptor co-agonist were first disclosed in March. https://www.firstwordpharma.com/story/5894192
-
EASD24: Novo's weight-loss drug Saxenda shines in paediatric obesity study https://firstwordpharma.com/story/5894295
-
Novo/DNB: Bivirkningsprofil for vægttabshåb lover godt for amylin-analoger https://proinvestor.com/investornyt/1212231/novo-dnb-bivirkningsprofil-for-vaegttabshab-lover-godt-for-amylin-analoger
-
Forget the shot. A weight loss pill saw promising results in Phase 1 testing | Fortune
Some users saw a 13% weight loss in three months.
Fortune (fortune.com)
-
Novo Jumps After New Pill Tops Wegovy; Lilly, Viking Shares Rise
Novo Nordisk stock rose moderately Wednesday after the pharma giant said its new weight-loss drug, amycretin, outperformed Wegovy.
Investor's Business Daily (www.investors.com)
-
Aktierne i Novo Nordisk blev sendt op med 4,2 pct. i USA onsdag aften, efter at selskabet har offentliggjort nyt om sin fedmepille.
Det skriver Bloomberg News, og det kan smitte af på det danske marked torsdag.
Det er den europæiske diabetesforening, EASD, der i disse dage afholder årsmøde, og her har Novo Nordisk løftet lidt af sløret for bivirkninger ved fedmepillen.
-
Sure opstød hos Roche-investorer efter fedmepille-bivirkninger https://proinvestor.com/investornyt/1212526/sure-opstod-hos-roche-investorer-efter-fedmepille-bivirkninger
-
Novo-analytiker om stigning: Færre bivirkninger trækker op https://proinvestor.com/investornyt/1212551/novo-analytiker-om-stigning-faerre-bivirkninger-traekker-op
-
Kort video: Den europæiske diabetesforening holder årsmøde i disse dage, og der fylder Novo selvfølgelig i landskabet, bl.a. med den fedmepille, de udvikler på. I forhold til Novo og amylin, så er der forbundne kar til andre danske selskaber inden for fedme som Zealand Pharma og Gubra - når det går godt for Novo, smitter det af på de to selskabers aktiekurser, som vi har set de sidste par dage. Og så er der regnskab fra Chemometec https://proinvestor.com/boards/122209/
-
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now https://proinvestor.com/investornyt/1212594/forget-eli-lilly-and-novo-nordisk-this-could-be-the-best-weight-loss-stock-to-buy-right-now
-
Novo-direktør: Ny pille er sikker og kan give 25 pct. vægttab https://borsen.dk/nyheder/virksomheder/novo-direktor-ny-pille-er-sikker-og-kan-give-25-pct-vaegttab?utm_source=nyhedsbrev&utm_medium=email&utm_campaign=13.09.24-morningbrief&utm_placement=15&utm_batch=3866e3c02f6d3c1#newsletter
-
Novo Nordisk signs $530M deal to leverage Korro's RNA editing tech for cardiometabolism https://firstwordpharma.com/story/5896118
-
Bernie er på banen igen. Ozempic bør koste 100$. NVO lukkede i 887 i U.S. https://www.nbcnews.com/health/health-news/bernie-sanders-says-ozempic-can-produced-less-100-month-rcna171493
-
Novo faldt i USA- handel: Direktør spår Ozempic kommer med i prisforhandling i USA https://proinvestor.com/investornyt/1215080/novo-faldt-i-usa-handel-direktor-spar-ozempic-kommer-med-i-prisforhandling-i-usa
-
Novo forudser Ozempic kommer med i næste prisforhandling i USA https://proinvestor.com/investornyt/1215079/novo-forudser-ozempic-kommer-med-i-naeste-prisforhandling-i-usa
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind